Boothbay Fund Management, LLC Bio Atla, Inc. Transaction History

Boothbay Fund Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$6.29 - $11.01 $67,258 - $117,729	10,693 New	10,693 $88,000
Q2 2022 Aug 15, 2022	BUY	$2.13 - $5.38 $26,625 - $67,250	12,500 New	12,500 $36,000
Q4 2021 Feb 14, 2022	SELL	$19.0 - $30.95 $482,847 - $786,532	-25,413 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$29.44 - $43.74 $394,996 - $586,859	13,417 Added 111.85%	25,413 $748,000
Q2 2021 Aug 16, 2021	BUY	$38.07 - $56.17 $93,537 - $138,009	2,457 Added 25.76%	11,996 $508,000
Q1 2021 May 17, 2021	BUY	$32.41 - $70.91 $309,158 - $676,410	9,539 New	9,539 $485,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.